Data Integrity Lapses Continue To Erode Wockhardt
Executive Summary
Details in US FDA’s latest warning letter for Indian site suggest that firm’s data integrity remediation efforts are not up to scratch at least yet. Agency’s observations also highlight the potential complexities that may be on hand for Cempra’s antibiotic Solithera, recently hit by a complete response letter.
You may also be interested in...
Warning Letters Special Report: The Decline And Fall Of Morton Grove Pharmaceuticals
It was bad enough that out-of-specification investigations were hugely inadequate, but the firm’s response to the FDA’s findings was even worse.
Antibiotics Pipeline Is Lively, But Sponsors Are Fragile
Regulatory uncertainty could imperil the crop of emerging companies making a go of it in the incentive-laden US anti-infective space.
How Indian Firms Are Rebooting For Quality Transformation
Against a backdrop of heightened regulatory scrutiny of manufacturing sites and processes, the heads of five top Indian firms told a recent forum in Mumbai how they are “rebooting” quality compliance and culture within their organizations. Tangible and intangible results are beginning to show but there is a long road ahead.